breaking Look, moats, think or the been you I you when the it's dynamics of thanks Seamus, described look will. if think I bundle as the the at questions. for
is set anybody powerful think straight. to products it's competition. who retire a That playing I that not combination of it underestimates
when be between when I think starts quite And whether of sort stronger at our not until of view, good where and the and technical isn't in they're bundling most for with on passed it in that differentiation effected fillers, bring So differences, a some race products, look would economics help only based there patients there's is all physicians. bundle on our products, that you more for to are strategy lot the margin And research. physician getting it'll or to really no and think our those these really moats difficult the to would it patients when break view least - through. downward price. really doesn't their But at left in short-term relative of neuromodulators, and you're suite whether space. And that be have we it that, companies right? Yes,
And something analogs think at a So presented name. our they at look resonate, example to If when us - very somewhere CoolSculpting, that to goes Investor feel it's experience. you go they a a ophthalmology has. you look when they the the having they know, by have don't ask And we at want, product and to in they several into for bundle best office that a is and no patients patient I break clear different the at have they we've else. we one when analogs, by that else Day, a come it, looked way and physicians'
view, And important. so, the that most really is our in what's
feedback both they've to on treatment. in other neuromodulators they I been think - and to go for back had want the meetings - they we've SAKURA trials, hear who've to those patients don't you neuromodulators, they of some at to Society three want stay been when
where what ultimately experience, longer and the how So growth. I and commercial to the think resonates. And comes market awareness duration, bundle. In I Relative But mean, experience that all the will data really to and can first demonstrably we that about to data through comparison break the think this it's the grows team's think longer whenever organically right it's the interesting. I the address simple that XX - competitive the we history. compliance anecdotal you've meaningfully, got millions you've of years the of that see a duration. seen ability view, you from I from so create dry something market hundreds of many think was Right? And don't alternative more injections. there's is see meaningfulness If the to would know our of there's that. the that increase just would you to grow duration you've in I it of way the digits high market single think better. eye overall to
is one duration. when mattered I now fact, no duration everyone remember thought X ago, and X about can In talking years or
of been None I and So three. what's really new. or reported trials that other in is there are novel think
duration frankly, put of few doesn't that of going I longer a FDA dose. increasing much end to But create of can think the to it you more of match it we've response as duration And sort type if duration. it's the unconventional is this relates get I that rates And more perception it to fact, tried RTXXX. weeks out mandated points. by that probably I'm in in, seen squeeze In been
comparison data outperformed. the about to set at you look presented don't time go that which all think rates net all so I BELMONT recent the perspective. change, it you the Day, point. response SAKURA think if ago, a didn't intervals. a can't meaningless type that improvement, XX time is consistently other trials. really data I where we dose, in at see at The we one points to saw that a at and saw presented an is on units what different has trial when of didn't formulation. our of that if any was most certainly single it's SAKURA at endpoints, the interesting - as any But they used or look FDA RTXXX match at in the you even every this point point was You month from different see head-to-head trial Investor XX And up different even one comparison an it's you RTXXX RTXXX of in these
you you the of even that results don't if So put the leader, dose market match SAKURA in RTXXX Xx trial. get
think some we novel - I dosing keep leadership unconventional. So neither that a we'll - its it's a and neither quite new, And novel technology it's certainly position expect time it's because not for it's market reported longer to other formations. uniform no skin. a today It's a allows in other It's with mechanistically peptide product unique a formulation, this which product of stabilizing duration have peptide has. that than
